These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 14639004)

  • 1. [VEGF-receptor inhibitors for anti-angiogenesis].
    Shibuya M
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):498-503. PubMed ID: 14639004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
    Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
    Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
    Schenone S; Bondavalli F; Botta M
    Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.
    Underiner TL; Ruggeri B; Gingrich DE
    Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.
    Shibuya M
    BMB Rep; 2008 Apr; 41(4):278-86. PubMed ID: 18452647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
    Shibuya M
    J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
    Mross K
    Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
    [No Abstract]   [Full Text] [Related]  

  • 14. VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
    Kiselyov A; Balakin KV; Tkachenko SE
    Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth.
    Ueda Y; Yamagishi T; Samata K; Ikeya H; Hirayama N; Okazaki T; Nishihara S; Arai K; Yamaguchi S; Shibuya M; Nakaike S; Tanaka M
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):16-24. PubMed ID: 15064856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor (VEGF) inhibition by small molecules.
    Ahmed SI; Thomas AL; Steward WP
    J Chemother; 2004 Nov; 16 Suppl 4():59-63. PubMed ID: 15688612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor and its inhibitors.
    Verheul HM; Pinedo HM
    Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
    Zhang C; Tan C; Ding H; Xin T; Jiang Y
    Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
    Tarallo V; De Falco S
    Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
    Eskens FA; Verweij J
    Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.